RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: A randomized, multicenter phase II trial
2017-01-01 Kim, Dong-Wan; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen L.; Hansen, Karin Holmskov; Kim, Sang-We; Huber, Rudolf M.; West, Howard L.; Groen, Harry J. M.; Hochmair, Maximilian J.; Leighl, Natasha B.; Gettinger, Scott N.; Langer, Corey J.; Rodríguez, Luis G. Paz-Ares; Smit, Egbert F.; Kim, Edward S.; Reichmann, William; Haluska, Frank G.; Kerstein, David; Camidge, D. Ross
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
2020-01-01 Camidge, D. R.; Kim, H. R.; Ahn, M. -J.; Yang, J. C. H.; Han, J. -Y.; Hochmair, M. J.; Lee, K. H.; Delmonte, A.; Garcia Campelo, M. R.; Kim, D. -W.; Griesinger, F.; Felip, E.; Califano, R.; Spira, A.; Gettinger, S. N.; Tiseo, M.; Lin, H. M.; Gupta, N.; Hanley, M. J.; Ni, Q.; Zhang, P.; Popat, S.
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
2021-01-01 Camidge, D. R.; Kim, H. R.; Ahn, M. -J.; Yang, J. C. H.; Han, J. -Y.; Hochmair, M. J.; Lee, K. H.; Delmonte, A.; Garcia Campelo, M. R.; Kim, D. -W.; Griesinger, F.; Felip, E.; Califano, R.; Spira, A. I.; Gettinger, S. N.; Tiseo, M.; Lin, H. M.; Liu, Y.; Vranceanu, F.; Niu, H.; Zhang, P.; Popat, S.
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
2018-01-01 Camidge, D. R.; Kim, H. R.; Ahn, M. -J.; Yang, J. C. -H.; Han, J. -Y.; Lee, J. -S.; Hochmair, M. J.; Li, J. Y. -C.; Chang, G. -C.; Lee, K. H.; Gridelli, C.; Delmonte, A.; Garcia Campelo, R.; Kim, D. -W.; Bearz, A.; Griesinger, F.; Morabito, A.; Felip, E.; Califano, R.; Ghosh, S.; Spira, A.; Gettinger, S. N.; Tiseo, M.; Gupta, N.; Haney, J.; Kerstein, D.; Popat, S.
Buccal mucosa cells as “in vivo” model to evaluate gefitinib activity in patients with advanced non-small cell lung cancer.
2007-01-01 Loprevite, M; Tiseo, M; Chiaramondia, M; Capelletti, M; Bozzetti, C; Bortesi, B; Naldi, N; Nizzoli, R; Dadati, P; Kunkl, A; Zennaro, D; Lagrasta, Costanza Anna Maria; Campanini, N; Spiritelli, E; Camisa, R; Grossi, F; Rindi, G; Franciosi, V; Ardizzoni, A.
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition?
2019-01-01 Leonetti, A.; Tiseo, M.; Rolfo, C.; Van Der Steen, N.; Peters, G. J.; Giovannetti, E.
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
2022-01-01 Terenziani, Rita; Galetti, Maricla; La Monica, Silvia; Fumarola, Claudia; Zoppi, Silvia; Alfieri, Roberta; Digiacomo, Graziana; Cavazzoni, Andrea; Cavallo, Delia; Corradi, Massimo; Tiseo, Marcello; Petronini, Pier Giorgio; Bonelli, Mara
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
2020-01-01 Dall'Olio, F. G.; Abbati, F.; Facchinetti, F.; Massucci, M.; Melotti, B.; Squadrilli, A.; Buti, S.; Formica, F.; Tiseo, M.; Ardizzoni, A.
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients
2015-01-01 Facchinetti, Francesco; Aldigeri, Raffaella; Aloe, Rosalia; Bortesi, Beatrice; Ardizzoni, Andrea; Tiseo, Marcello
Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis
2021-01-01 Liu, Y.; Yang, S.; Zhao, J.; He, Z.; Ma, J.; Guo, Y.; Wang, W.; Yoshizawa, A.; Prelaj, A.; Tiseo, M.; Normanno, N.; Van Schil, P. E.; Wang, Q.; Yang, X.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: A randomized, multicenter phase II trial | 1-gen-2017 | Kim, Dong-Wan; Tiseo, Marcello; Ahn, Myung-Ju; Reckamp, Karen L.; Hansen, Karin Holmskov; Kim, Sang-We; Huber, Rudolf M.; West, Howard L.; Groen, Harry J. M.; Hochmair, Maximilian J.; Leighl, Natasha B.; Gettinger, Scott N.; Langer, Corey J.; Rodríguez, Luis G. Paz-Ares; Smit, Egbert F.; Kim, Edward S.; Reichmann, William; Haluska, Frank G.; Kerstein, David; Camidge, D. Ross | |
| Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial | 1-gen-2020 | Camidge, D. R.; Kim, H. R.; Ahn, M. -J.; Yang, J. C. H.; Han, J. -Y.; Hochmair, M. J.; Lee, K. H.; Delmonte, A.; Garcia Campelo, M. R.; Kim, D. -W.; Griesinger, F.; Felip, E.; Califano, R.; Spira, A.; Gettinger, S. N.; Tiseo, M.; Lin, H. M.; Gupta, N.; Hanley, M. J.; Ni, Q.; Zhang, P.; Popat, S. | |
| Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial | 1-gen-2021 | Camidge, D. R.; Kim, H. R.; Ahn, M. -J.; Yang, J. C. H.; Han, J. -Y.; Hochmair, M. J.; Lee, K. H.; Delmonte, A.; Garcia Campelo, M. R.; Kim, D. -W.; Griesinger, F.; Felip, E.; Califano, R.; Spira, A. I.; Gettinger, S. N.; Tiseo, M.; Lin, H. M.; Liu, Y.; Vranceanu, F.; Niu, H.; Zhang, P.; Popat, S. | |
| Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer | 1-gen-2018 | Camidge, D. R.; Kim, H. R.; Ahn, M. -J.; Yang, J. C. -H.; Han, J. -Y.; Lee, J. -S.; Hochmair, M. J.; Li, J. Y. -C.; Chang, G. -C.; Lee, K. H.; Gridelli, C.; Delmonte, A.; Garcia Campelo, R.; Kim, D. -W.; Bearz, A.; Griesinger, F.; Morabito, A.; Felip, E.; Califano, R.; Ghosh, S.; Spira, A.; Gettinger, S. N.; Tiseo, M.; Gupta, N.; Haney, J.; Kerstein, D.; Popat, S. | |
| Buccal mucosa cells as “in vivo” model to evaluate gefitinib activity in patients with advanced non-small cell lung cancer. | 1-gen-2007 | Loprevite, M; Tiseo, M; Chiaramondia, M; Capelletti, M; Bozzetti, C; Bortesi, B; Naldi, N; Nizzoli, R; Dadati, P; Kunkl, A; Zennaro, D; Lagrasta, Costanza Anna Maria; Campanini, N; Spiritelli, E; Camisa, R; Grossi, F; Rindi, G; Franciosi, V; Ardizzoni, A. | |
| Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? | 1-gen-2019 | Leonetti, A.; Tiseo, M.; Rolfo, C.; Van Der Steen, N.; Peters, G. J.; Giovannetti, E. | |
| CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells | 1-gen-2022 | Terenziani, Rita; Galetti, Maricla; La Monica, Silvia; Fumarola, Claudia; Zoppi, Silvia; Alfieri, Roberta; Digiacomo, Graziana; Cavazzoni, Andrea; Cavallo, Delia; Corradi, Massimo; Tiseo, Marcello; Petronini, Pier Giorgio; Bonelli, Mara | |
| CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors | 1-gen-2020 | Dall'Olio, F. G.; Abbati, F.; Facchinetti, F.; Massucci, M.; Melotti, B.; Squadrilli, A.; Buti, S.; Formica, F.; Tiseo, M.; Ardizzoni, A. | |
| CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients | 1-gen-2015 | Facchinetti, Francesco; Aldigeri, Raffaella; Aloe, Rosalia; Bortesi, Beatrice; Ardizzoni, Andrea; Tiseo, Marcello | |
| Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis | 1-gen-2021 | Liu, Y.; Yang, S.; Zhao, J.; He, Z.; Ma, J.; Guo, Y.; Wang, W.; Yoshizawa, A.; Prelaj, A.; Tiseo, M.; Normanno, N.; Van Schil, P. E.; Wang, Q.; Yang, X. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Articolo su rivista 338
- 1 Articolo su rivista::1.1 Artico... 338
Data di pubblicazione
- 2020 - 2024 116
- 2010 - 2019 193
- 2003 - 2009 29
Editore
- Elsevier Ltd 10
- Elsevier Ireland Ltd 9
- AME Publishing Company 8
- Elsevier Inc. 8
- MDPI 6
- Lippincott Williams and Wilkins 5
- MDPI AG 5
- SAGE Publications Ltd 5
- American Association for Cancer R... 4
- Future Medicine Ltd. 4
Rivista
- LUNG CANCER 31
- JOURNAL OF THORACIC ONCOLOGY 20
- CLINICAL LUNG CANCER 19
- TUMORI 14
- CANCERS 12
- EUROPEAN JOURNAL OF CANCER 12
- TRANSLATIONAL LUNG CANCER RESEARCH 12
- ANNALS OF ONCOLOGY 9
- IMMUNOTHERAPY 9
- BRITISH JOURNAL OF CANCER 8
Keyword
- Humans 107
- Lung Neoplasms 92
- Carcinoma 70
- Non-Small-Cell Lung 66
- Female 59
- Male 59
- Middle Aged 56
- Aged 48
- NSCLC 48
- Adult 39
Lingua
- eng 324
Accesso al fulltext
- no fulltext 248
- open 64
- reserved 19
- partially open 7